If you do not know which department is competent, please send your question to the joint Health Service Centre of the FAMHP, the FPS Public Health and the NIHDI:

  • to the FAMHP general email address:;
  • or by phone + 32 2 528 40 00 (available on working days from 8 a.m. to 1 p.m.). The telephone lines of the Health Service Centre are operational again for calls in French. The Service Centre can, however, be reached via e-mail in both Dutch and French. The technical problems should be resolved by 1 August 2024.

Please contact us preferably by e-mail.

Your question will be forwarded to the relevant department.

Send your questions to a single email address of the FAMHP. Below you will find the correct contact address for each type of question.

General contacts

Type of question

Reception desk or questions for which you cannot find specific contact information
+ 32 2 528 40 00 (available on working days
from 8 a.m. to 1 p.m.)
Questions for the secretariat of the Chief Executive Officer, Hugues Malonne
Press questions
+ 32 2 528 40 12

Spokesperson (Ann Eeckhout)
+ 32 495 23 71 69

Complaints Complaint form
Reporting of irregularities within the areas of competence of the FAMHP by whistleblowers

Agreement on whistleblowers
The federal ombudsman - Whistleblowers

Questions concerning legislation and disputes

Specific question regarding the identity of controllers and inspectors staff 
(For privacy reasons, the names of controllers and inspectors of DG Inspection of the FAMHP are not made public.)

Questions about customer invoicing (invoices from the FAMHP)

Questions about supplier invoicing (invoices for the FAMHP)

Questions and comments about the FAMHP website
Hospital audit questions Federal supervision and audit of hospitals
Urgent medical questions Contact your doctor or pharmacist
Contact the Antipoison Centre
(available 24/7 on + 32 70 245 245)



Type of question


Applications for Scientific-Technical and regulatory advice (WTA)

Applications for advice on the regulatory status of a borderline product

Questions about (pre)clinical research and development of new drugs, therapies and innovative technologies

Applications for Certificates of Pharmaceutical Products (CPP), certified copies, SEEN certificates and other related documents
Application for manufacturing/importation authorization for medicinal products (MIA), for wholesale distributor authorization for medicinal products (WDA) and for registrations of active substances (API)

Questions about a Marketing Authorisation for a medicine for human use

Applications for new authorisations (centralised procedure, national procedure and mutual or decentralised recognition procedure (MRP or DCP))

Applications for variations and renewals

Questions on the proper use of medicines

Questions about distribution activities of Active Pharmaceutical Ingredients or medicines
Questions about the pharmaceutical activities (storage, preparation and delivery of human and veterinary medicines) in pharmacies open to the public or hospital pharmacies

Questions about inspections of manufacturers of medicines, raw materials of Active Pharmaceutical Ingredients and about Good Manufacturing Practices (GMP)

Questions about inspections of clinical trial stakeholders (sponsors, CRO, Ethics Committees, phase 1 centres, research sites, etc.) and Good Clinical Practices (GCP)

Questions on accreditation of qualified persons, market surveillance and quality issues

Questions about pharmacovigilance inspections and the tasks and responsibilities of the marketing authorisation holder for a medicine
Questions about inspections of publicity and other promotional activities for medicines
Questions about homeopathic medicines

Questions about veterinary medicines including questions on

  • marketing authorisations;
  • parallel imports;
  • clinical trials;
  • publicity and promotion;
  • distribution.
Questions about the availability and commercialisation of medicines
Questions for the National Innovation Office such as:
  • requests for Project Information Meetings where research is informally presented at an early stage
  • requests for Portfolio Meetings
  • questions about research and development of new medicines, treatments and innovative technologies
Questions about publicity, notification and visas

Questions on submitted clinical trials

Safety-related questions on clinical trials submitted under Regulation 536/2014 (CTR)

Questions about Compassionate Use and Unmet Medical Need programmes
Questions about narcotics and psychotropic substances

Questions about pharmacovigilance

Questions about adverse reactions

Reporting adverse reactions
(medicines for human use)

Reporting adverse reactions
(medicines for veterinary use) (NL) (FR) (NL) (FR)

Questions about inspections and controls
Questions on illegal practices (Special Investigation Unit)


Medical devices

Type of question Contact

Questions on

  • qualification
  • classification
  • invitations for European/national meetings

All other questions and enquiries about subjects that do not qualify for other email addresses

Questions about clinical trials

Questions about performance studies

Questions about serious adverse events

Applications for Scientific-Technical and Regulatory advice for innovative devices (medical devices, in vitro diagnostics (IVD), combination products of a medical device with a medicine or human body material ...)

Applications for advice from a Notified Body to the FAMHP

Applications for advice on the regulatory status of a borderline product

Questions about (pre)clinical research and development of new medicines, therapies and innovative technologies
Questions about Notified Bodies and Notified Body certificates (withdrawal, suspension, etc.)

Questions for and about certificates of free sale

Questions about Compassionate Use

Questions about derogations

Questions about appeals

All vigilance related documents and questions:

  • (serious) incident
  • Manufacturer Incident Report (MIR)
  • Periodic Summary Report (PSR)
  • Field Safety Corrective Action (FSCA)
  • Field Safety Notice (FSN)
  • Trend report
  • Post Market Surveillance (PMS) report
  • Periodic Safety Update Report (PSUR) + evaluation
  • Breast Implant Associated – Anaplastic Large Cell Lymphoma (BIA-ALCL)
  • All security and safety issues with devices

Questions about the Central Traceability Register
Questions about:
  • inspection dossiers
  • advertising and promotion of medical devices
  • self-checking guide (Good Distribution Practices)
  • the section “My control/Self-checking form” on the FAMHP portal
  • violations of the medical devices and IVD legislations by registered actors
Questions about fraud, prosecution dossiers, violations of the legislation on medical devices and IVDs by non-registered actors

Questions about marketing and distribution notifications

Questions about registration of actors

Questions about online applications (except the web portal of the FAMHP)

Questions about registration in EUDAMED

All technical questions relating to the online applications and the web portal (except questions about EUDAMED)

+32 2 528 48 56

Technical issues with EUDAMED
Questions about contributions
Questions about the implementation of Regulations (EU) 2017/745 and (EU) 2017/746

Questions about inspections and controls
Questions about illegal practices (Special Investigation Unit)


Special products

Type of question Contact
Questions about inspection and control of human body material
Questions about human body material
Questions about drug precursors

Questions about products in the "grey area" of which the status is unclear

for human use

for veterinary use

Questions and documents about the vigilance of blood and blood products
Questions and documents about the vigilance of human body material (cells and tissue)

Follow us on social media
Picture_FB Picture_X_Twitter Picture_Linkin

Federal Agency for Medicines and Health Products
Avenue Galilée 5/03

The building is open from 8 a.m. till 7 p.m.

Map: PNG - PDF
Google Maps


Welcome to the Galilee building
More information on car park, accessibility and facilities


Last updated on 04/07/2024